A cost‐effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer

Many western countries have established female human papillomavirus (HPV) vaccination programs for the prevention of cervical cancer. The quadrivalent HPV vaccine (HPV4) has proven efficacy against additional HPV‐related disease in both sexes, but the cost effectiveness of male HPV vaccination remains controversial. To assess the cost effectiveness of male HPV vaccination in Canada with respect to oropharyngeal cancer (OPC), the authors performed a preliminary cost‐effectiveness analysis.

[1]  H. Jessen,et al.  Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. , 2011, The New England journal of medicine.

[2]  E. Joura,et al.  Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost–effectiveness analysis , 2014, Expert review of pharmacoeconomics & outcomes research.

[3]  S. Wilson.  Methods for the economic evaluation of health care programmes , 1987 .

[4]  P. Warde,et al.  Cost-effectiveness of intensity-modulated radiotherapy in oropharyngeal cancer. , 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).

[5]  R. Guy,et al.  Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. , 2011, The Lancet. Infectious diseases.

[6]  D. Ekwueme,et al.  The cost-effectiveness of male HPV vaccination in the United States. , 2011, Vaccine.

[7]  Johannes A Langendijk,et al.  Quality of life after surgical treatment for oral and oropharyngeal cancer: a prospective longitudinal assessment of patients reconstructed by a microvascular flap. , 2007, Oral oncology.

[8]  D. Lowy,et al.  Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica , 2013, PloS one.

[9]  A. Hui,et al.  Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Boily,et al.  Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis. , 2010, Vaccine.

[11]  Brenna D. Shearer.  HPV Vaccination: Understanding the Impact on HPV Disease , 2011 .

[12]  三澤吉雄.  In Canada … , 1980, Current History.

[13]  C. R. Leemans,et al.  Employment and return to work in head and neck cancer survivors. , 2010, Oral oncology.

[14]  P. Lopalco,et al.  The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[15]  C. Quach,et al.  National Advisory Committee on Immunization (NACI). , 1989, Canada diseases weekly report = Rapport hebdomadaire des maladies au Canada.

[16]  Edson Duarte Moreira Júnior,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. , 2007, The New England journal of medicine.

[17]  M. Boily,et al.  Different population-level vaccination effectiveness for HPV types 16, 18, 6 and 11 , 2010, Sexually Transmitted Infections.

[18]  P. De Wals,et al.  The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. , 2007, Vaccine.

[19]  P. Sparén,et al.  Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. , 2012, The Journal of infectious diseases.

[20]  Daron G Ferris,et al.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. , 2007, The New England journal of medicine.

[21]  X. Castellsagué,et al.  Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women , 2006, Pediatrics.

[22]  J. Waldron,et al.  Comorbidity and prognosis in head and neck cancers: Differences by subsite, stage, and human papillomavirus status , 2014, Head & neck.

[23]  M. Zahurak,et al.  Tissue Distribution of Human Papillomavirus 16 DNA Integration in Patients with Tonsillar Carcinoma , 2005, Clinical Cancer Research.

[24]  S. Goldie,et al.  Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States , 2009, BMJ : British Medical Journal.

[25]  Carole Fakhry,et al.  Case-control study of human papillomavirus and oropharyngeal cancer. , 2007, The New England journal of medicine.

[26]  H. Jessen,et al.  HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. , 2011, The New England journal of medicine.

[27]  T. Gorlia,et al.  Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  H. Brenner,et al.  Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. , 2010, The oncologist.

[29]  Esther Kim,et al.  Human papillomavirus and rising oropharyngeal cancer incidence in the United States. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  E. Lynge,et al.  Introduction of human papillomavirus vaccination in Nordic countries. , 2012, Vaccine.

[31]  K. Bjordal,et al.  Quality of Life and Head and Neck Cancer: A 5 Year Prospective Study , 2005, The Laryngoscope.

[32]  Robert N. Anderson,et al.  Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage Levels , 2013, Journal of the National Cancer Institute.

[33]  Elamin H Elbasha,et al.  Impact of vaccinating boys and men against HPV in the United States. , 2010, Vaccine.

[34]  F. Hilgers,et al.  First‐year quality of life assessment of an intra‐arterial (RADPLAT) versus intravenous chemoradiation phase III trial , 2009, Head & neck.

[35]  M. Pawlita,et al.  Seroprevalence and Determinants of Eight High-Risk Human Papillomavirus Types in Homosexual Men, Heterosexual Men, and Women: A Population-Based Study in Amsterdam , 2010, Sexually transmitted diseases.

[36]  A. Giuliano,et al.  The Epidemiology of Oral HPV Infection among a Multinational Sample of Healthy Men , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[37]  J. Hocking,et al.  Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women , 2009, Sexually Transmitted Infections.

[38]  Kelvin K. W. Chan,et al.  Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study. , 2013, CMAJ open.

[39]  F. X. Bosch,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions , 2007 .

[40]  A. Oshima,et al.  Trends in head and neck cancer incidence in Japan during 1965-1999. , 2005, Japanese journal of clinical oncology.

[41]  C. Wheeler,et al.  A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions , 2009, Cancer Prevention Research.

[42]  A. Giuliano,et al.  Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study , 2013, The Lancet.

[43]  M. Schiffman,et al.  Updating the natural history of human papillomavirus and anogenital cancers. , 2012, Vaccine.

[44]  G. Zaric,et al.  Cost-Effectiveness of Adding Cetuximab to Platinum-Based Chemotherapy for First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer , 2012, PloS one.

[45]  A. Hui,et al.  The changing incidence of human papillomavirus-associated oropharyngeal cancer using multiple imputation from 2000 to 2010 at a Comprehensive Cancer Centre. , 2013, Cancer epidemiology.

[46]  E. Vogtmann,et al.  The cost burden of oral, oral pharyngeal, and salivary gland cancers in three groups: commercial insurance, medicare, and medicaid , 2012, Head & neck oncology.

[47]  D. Gertig,et al.  Catching up with the catch-up: HPV vaccination coverage data for Australian women aged 18-26 years from the National HPV Vaccination Program Register. , 2011, Communicable diseases intelligence quarterly report.

[48]  K. Ang,et al.  Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.

[49]  M. Bridger,et al.  Trends in the incidence rates of tonsil and base of tongue cancer in England, 1985-2006. , 2010, Annals of the Royal College of Surgeons of England.

[50]  S. Johnson-Obaseki,et al.  Head and Neck Cancer in Canada , 2012, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[51]  Philadelphia County,et al.  Human Papillomavirus Vaccination Coverage Among Adolescent Girls, 2007-2012, and Postlicensure Vaccine Safety Monitoring, 2006-2013 — United States , 2013 .

[52]  B. Graubard,et al.  Prevalence of oral HPV infection in the United States, 2009-2010. , 2012, JAMA.

[53]  Christian Munk,et al.  Trends in head and neck cancer incidence in Denmark, 1978–2007: Focus on human papillomavirus associated sites , 2011, International journal of cancer.